Brainchip Holdings Ltd

BRN

BrainChip Holdings Ltd. engages in the development of software and hardware solutions for artificial intelligence and machine learning applications. The company is headquartered in Sydney, New South Wales and currently employs 78 full-time employees. The company went IPO on 2011-11-09. The Company’s software and hardware accelerated solutions for advanced AI and machine learning applications with a primary focus on the development of its Akida Neuromorphic Processor. The Company’s fully digital, event-based AI processor, Akida, uses neuromorphic principles to mimic the human brain, analyzing only essential sensor inputs at the point of acquisition, processing data with unparalleled efficiency, precision, and economy of energy. Akida enables Edge learning local to the chip, independent of the cloud, reducing latency while improving privacy and data security. Its other products include MetaTF, 2nd Generation akida, Akida1000 reference chip and Akida Enablement Platforms. Akida Enablement Platforms include Akida PCIe Board, Akida Development Kit Shuttle PC, and Akida Development Kit Raspberry Pi.

Brickworks Limited

BKW

Brickworks Ltd. engages in the manufacture and distribution of building products. The company is headquartered in Sydney, New South Wales and currently employs 1,850 full-time employees. Its segments include Building Products Australia, Building Products North America, Property and Investments. Building Products Australia and Building Products North America segments manufacture and supply vitrified clay and concrete products used in the building industry. Building Products Australia segment includes Austral Bricks (bricks producer) and other brands such as Austral Masonry and Bristile Roofing. Building Products North America segment includes the flagship brand of Glen-Gery. This segment's product lines include bricks, masonry blocks and accessories. Property segment utilizes opportunities associated with land owned by the Company, including the sale of property and investment in Property Trusts. Investments segment holds investments in the Australian share market, both for dividend income and capital growth, and includes the investment in Washington H. Soul Pattinson and Company Limited, and FBR Limited.

Hot Chili Limited

HCH

Hot Chili Ltd. engages in the identification, acquisition, exploration, evaluation, and development of mineral deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-05-03. The principal activity of the Company is engaged in mineral exploration. The firm is focused on copper exploration and development in Chile’s Atacama Region. The Company’s Costa Fuego Project is a copper mining hub in Region III on the Chilean coastal range. Its Chilean coastal range Costa Fuego Copper-Gold Project comprises the Cortadera, Productora and San Antonio deposits. The Cortadera deposit is focused on copper-gold discoveries in Chile. Productora is an advanced-stage copper-gold project. Its El Fuego copper Project encompasses two historic underground mines, which include San Antonio and Valentina. The Company’s wholly owned subsidiaries include Sociedad Minera El Corazon Limitada, Sociedad Minera Los Mantos SpA, Sociedad Minera Frontera SpA, and Sociedad Minera Bandera SpA.

Mesoblast Limited

MSB

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.

Paradigm Biopharmaceuticals Limited.

PAR

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is engaged in discovering, developing, and delivering pharmaceutical therapies. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). The company develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).